Marella Thorell

Chief Financial Officer, Seres Therapeutics, Inc.

Leaving, effective November 15, 2026. First published here October 28, 2026; built from records as of October 28, 2026.

Marella Thorell is leaving the chief financial officer seat at Seres Therapeutics, Inc.: the company's filing of October 26, 2026 gives November 15, 2026 as the effective date.¹

Seats

The seat in the record

Company	Title as filed	Standing	Filings
Seres Therapeutics, Inc. (MCRB)	Not stated	Leaving, effective November 15, 2026	1

Company names link to the company's page in the record at CFO Tribune, which holds the seat history.

The record

Filing by filing, latest first

November 15, 2026takes effect
Seres Therapeutics, Inc. reported the departure of Marella Thorell from the chief financial officer seat, effective November 15, 2026.
On October 22, 2026, Marella Thorell, Executive Vice President and Chief Financial Officer of Seres Therapeutics, Inc. (the “Company”), resigned from her positions as Executive Vice President and Chief Financial Officer of the Company, effective November 15, 2026 […]
[1] Filing by Seres Therapeutics, Inc., filed with the SEC on October 26, 2026. Read the filing. The record at CFO Tribune.

Sources

Current report filed with the SEC, Seres Therapeutics, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed October 26, 2026. sec.gov; record.

Corrections and removal

If a line here is wrong, or Marella Thorell wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.